Newly Discovered Marker Means More Patients Benefiting from Immunotherapy

James expert Dr. Sameek Roychowdhury explains how cancer patients with a newly discovered cell marker called MSI (micro-satellite instability) are very likely to benefit from immunotherapy – novel therapies that boost patients’ immune systems to help them fight cancer.

MSI most frequently shows up in colorectal and endometrial (uterine) cancers, but James experts have found that the marker is sometimes presents in other cancers, indicating that those patients could greatly benefit from immunotherapy as well.